

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LIANG *et al.*

Appl. No.: 10/531,049; § 371 Date:
January 17, 2006

U.S. Nat'l Phase of PCT/CN2002/000728;
I.A. Fd: October 17, 2002

For: **A Natural Compound for
Prevention and Treatment of
Diabetes, Process for Preparing the
Same, and Pharmaceutical Use
Thereof (as amended)**

Confirmation No.: 5056

Art Unit: 1621

Examiner: KEYS, Rosalynd Ann

Atty. Docket: 2108.0060000/MAC

**Third Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(c)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form PTO/SB/08B are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on January 15, 2008 in connection with the above-captioned application.

Copies of documents, **NPL14** to **NPL21**, are submitted.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before close of prosecution in the application. The required fee is provided through online credit card payment authorization in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

Date: January 22, 2009

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
927330v1